Stockscreener 앱 받기
2.71
2.17%
-0.06
시간 외 거래:
2.71
Adverum Biotechnologies Inc 주식(ADVM)의 최신 뉴스
What analysts say about Adverum Biotechnologies Inc. stockFree Investment Risk Control - Autocar Professional
What drives Adverum Biotechnologies Inc. stock priceConsistently superior profits - PrintWeekIndia
Adverum Biotechnologies Inc. Stock Analysis and ForecastSuperior risk-adjusted returns - PrintWeekIndia
Is Adverum Biotechnologies Inc. a good long term investmentUnstoppable trading performance - Autocar Professional
Presenting on Emerging Growth Conference 84 Day 2 on July 17; Register to live stream - GlobeNewswire Inc.
How Adverum Biotechnologies Inc. stock performs during market volatilityFree Access to Investment Community - Newser
what makes adverum biotechnologies inc. stock price move sharplyDaily Volume Leaders - Newser
What makes Adverum Biotechnologies Inc. stock price move sharplyFree Access to Community - Newser
Why Adverum Biotechnologies Inc. stock attracts strong analyst attentionProven High Yield Signals - Newser
Adverum Biotechnologies Up 22%, Insiders Still Down After US$526.8k Purchase - simplywall.st
Reversal Of Fortune For Adverum Biotechnologies Insiders Who Made A US$526.8k Purchase - Yahoo Finance
Adverum Biotechnologies, Inc.(NasdaqCM: ADVM) dropped from Russell 3000 Index - MarketScreener
Adverum Biotechnologies shareholders approve stock option repricing - Investing.com
Adverum Biotechnologies shareholders approve stock option repricing By Investing.com - Investing.com India
Adverum Biotechnologies’ SWOT analysis: gene therapy stock faces pivotal year - Investing.com Nigeria
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Adverum Biotechnologies (NASDAQ:ADVM) versus Metagenomi (NASDAQ:MGX) Head-To-Head Analysis - Defense World
Adverum Awards 14,610 Shares in Stock Options and RSUs to Key New Hires - Stock Titan
Adverum Biotechnologies Reports Q1 2025 Financial Results - TipRanks
Adverum Biotechnologies (ADVM) Sees Price Target Adjustment by RBC Capital | ADVM Stock News - GuruFocus
Adverum Biotechnologies (ADVM) Receives Continued Buy Rating from Chardan Capital | ADVM Stock News - GuruFocus
Adverum Biotechnologies (ADVM) Price Target Reduced by RBC Capit - GuruFocus
Adverum Biotechnologies (ADVM) Rating Reiterated at 'Buy' by HC Wainwright | ADVM Stock News - GuruFocus
RBC Cuts Price Target on Adverum Biotechnologies to $4 From $5, Keeps Sector Perform, Speculative Risk - marketscreener.com
Adverum Biotechnologies: Q1 Earnings Snapshot - CT Insider
Adverum (ADVM) Projects Funding Through Late 2025 | ADVM Stock N - GuruFocus
Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights - The Manila Times
Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline ... - Bluefield Daily Telegraph
Revolutionary One-Time Gene Therapy Shows 3.5-Year Vision Protection in Wet AMD Patients - Stock Titan
Adverum Biotechnologies Inc (ADVM)’s Market Momentum: Closing Strong at 3.23, Down -10.03 - DWinneX
Adverum Biotechnologies’ SWOT analysis: gene therapy firm faces pivotal year - Investing.com Nigeria
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc.ADVM - PR Newswire
0.87%
0.17%
자본화:
|
볼륨(24시간):